Article
Identification of 6,9-dihydro-5H-pyrrolo[3,2-h]quinazolines as a new class of F508del-CFTR correctors for the treatment of cystic fibrosis.
European journal of medicinal chemistry - 5 Oct 2024
Barreca Marilia, Renda Mario, Spanò Virginia, Montalbano Alessandra, Raimondi Maria Valeria, Giuffrida Stefano, Bivacqua Roberta, Bandiera Tiziano, Galietta Luis J V, Barraja Paola
Abstract excerpt
Although substantial advances have been obtained in the pharmacological treatment of cystic fibrosis (CF) with the approval of Kaftrio, a combination of two correctors (VX-661, VX-445) and one potentiator (VX-770), new modulators are still needed to rescue F508del and other CFTR mutants with trafficking defects. We have previously identified PP compounds based on a tricyclic core as correctors with high efficacy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
